Three finalists selected for SwedenBIO’s annual life science award

This year’s three finalists for the annual SwedenBIO Award exemplifies both the innovative power and the business acumen of Swedish companies.

SwedenBIO Award finalists 2022

The SwedenBIO Award is bestowed upon a company that has made a noteworthy contribution to the life science ecosystem in the past year, and – through its contributions to society – has demonstrated the importance of a thriving life science industry in Sweden.

SwedenBIO Award is the industry’s own prize and is given in collaboration with HealthCap. The award has been handed out since 2007 to put the spotlight on successful and inspiring companies. The three finalists for 2022 have now been selected.

We’re proud to present this year’s SwedenBIO Award finalists, in alphabetical order:

Antaros Medical is a fast growing company specialised in imaging technologies that support clinical drug development projects in understanding how medicines work in the human body. This innovative approach increases our understanding of relevant disease biology and offers a wide range of applications to develop medicines for several unmet medical needs. The company invests heavily in innovation and R&D, which has resulted in an impressive number of collaboration projects with drug companies around the world.

Genovis offers a wide range of enzyme-based tools that allow for faster research and development activities for their customers. Access to new innovative enzyme products enable the development and quality control of biological drugs and advanced therapy medicinal products, which are crucial for advancing drug development of antibody-based treatments and gene therapy. The company has launched several products and partnered with a number of international companies, resulting in rapid growth.

Hansa Biopharma develops antibody-cleaving enzymes that target pathogenic or disease-causing antibodies. Their broad therapeutic pipeline offers application possibilities for several unmet medical needs, such as transplantation, autoimmune diseases, gene therapy, and oncology. The company’s first-in-class IgG antibody-cleaving enzyme therapy for kidney-transplantation-sensitized patients is approved in the EU and is actively commercialized by the company, while clinical trials supporting label extension is ongoing.

The winner is announced on December 6, 2022, at the SwedenBIO Summit conference at Grand Hôtel in Stockholm.

The jury consist of SwedenBIO’s board: Lotta Ljungqvist, 4L Bioconsulting; Christine Wesström, Sobi; Anders Persson, AstraZeneca; Kertin Falck, Pfizer; Niels Abel Bonde, Novo Nordisk Sweden; Carl Kilander, HealthCap; Sana Alajmovic, Sigrid Therapeutics; and Torkel Gren, Recipharm.

Journalists from established news outlets are invited to attend the award ceremony, which concludes SwedenBIO Summit. Contact Alexandra Hoegberg, Director of Communications and International Marketing, for more information.

Read the press release here.